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Systemic AA Amyloidosis Caused by Inflammatory 
Hepatocellular Adenoma
To the Editor: Amyloid A (AA) systemic amy­
loidosis is a complication of chronic inflamma­
tory diseases that is caused by the deposition of 
insoluble aggregates of cleaved N­terminal frag­
ments of serum amyloid A (SAA) protein in tis­
sues and organs throughout the body.1 Under 
physiologic conditions, SAA protein is produced 
by hepatocytes during the acute inflammatory 
phase in response to various cytokines such as 
interleukin­6. SAA is also overexpressed by neo­
plastic hepatocytes in inflammatory hepatocel­
lular adenomas, a specific molecular subtype of 
benign liver tumors.2,3
Here, we describe a 49­year­old female patient 
who presented with diarrhea, rectal bleeding, and 
leg edema and received a diagnosis of systemic 
AA amyloidosis. Clinical characteristics of the 
patient are provided in Table S1 in the Supple­
mentary Appendix, available with the full text of 
this letter at NEJM.org. An inflammatory hepato­
cellular adenoma was identified and resected, 
resulting in the improvement of amyloidosis­
related symptoms, with progressive normaliza­
tion of the serum C­reactive protein (Fig. 1A) and 
SAA levels. Unfortunately, the patient’s kidney 
function did not improve, and she died 18 months 
after surgery from fulminant septic shock.
Whole­genome sequencing of the inflamma­
tory hepatocellular adenoma revealed a complex 
structural rearrangement on chromosome 7 with 
an inversion leading to the truncation of the IL6 
3′ untranslated region (3′UTR), which comprises 
key sequences involved in the degradation of this 
unstable transcript (Fig. 1, and Tables S2 and S3 
Figure 1 (facing page). Biologic, Imaging, Pathological, 
and Molecular Findings in Our Patient.
As shown in Panel A, liver resection was followed by a 
clinically significant decrease in serum levels of C-reactive 
protein (CRP) (top), and magnetic resonance imaging 
showed a heterogeneous, 5-cm liver mass at the tip of 
segment VI on T2-weighted sequences (bottom, arrow). 
As shown in Panel B, microscopic examination of the re-
sected specimen revealed a well-differentiated tumor with 
massive amyloid deposits (arrows) (subpanel a, Congo 
red staining, low magnification) and typical yellow-green 
birefringence under polarized light (subpanel b, low mag-
nification). Immunohistochemical tests showed positive 
staining for serum amyloid A (SAA) protein in neoplastic 
hepatocytes (black arrows) and amyloid deposits (red 
arrows) in the tumor (T) sample (subpanel c, high mag-
nification); SAA expression was also observed in the ad-
jacent nontumorous (NT) parenchyma (subpanel d, high 
magnification). CRP was expressed in the tumor (T) (sub-
panel e, low magnification) (neoplastic hepatocytes, black 
arrows) and the adjacent NT liver tissue (subpanel f, high 
magnification) (non-neoplastic hepatocytes, black arrows). 
As shown in Panel C, whole-genome sequencing of the tu-
mor sample obtained from the patient revealed a cluster 
of somatic structural rearrangements at the IL6 locus on 
chromosome 7. The blue line in the outer circle indicates 
copy number, and structural rearrangements are indicated 
in the inner circle. Red indicates deletion, blue inversion, 
gray interchromosomal translocation, and black classic 
chromatin staining of the cytobands. As shown in Panel D, 
although overexpression of IL6 was specific to the tumor 
sample, the genes SAA1 and CRP were also massively over-
expressed in the adjacent liver tissue, as compared with 
normal liver tissue. FPKM denotes fragments per kilobase 
of exon per 1 million reads in the RNA sequencing experi-
ment. As shown in Panel E, chromosomal inversion with 
one breakpoint located in the 3′  untranslated region (UTR) 
of the gene IL6 and the other breakpoint in an intergenic 
region at 7p14.1 led to the massive overexpression of an 
interleukin-6 transcript lacking regulatory 3′UTR elements 
in the patient’s tumor (top, structural rearrangement identi-
fied by means of whole-genome sequencing; bottom, gene 
expression and transcript structure identified by means 
of RNA sequencing). AU denotes adenylate–uridylate.
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in the Supplementary Appendix). RNA sequenc­
ing consistently showed a massive overexpres­
sion of an interleukin­6 transcript lacking all 3′ 
regulatory elements; this overexpression was 
limited to the tumor area. However, in contrast 
to classic inflammatory hepatocellular adenoma, 
we observed overexpression of SAA in both the 
tumor and nontumorous liver. Amyloid deposits 
were also identified in the adenoma and the 
adjacent parenchyma (Fig. 1). These results sup­
port an autonomous production of interleukin­6 
by the inflammatory hepatocellular adenoma 
with activation of a paracrine Janus kinase–signal 
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(JAK–STAT3) pathway in the liver (Fig. S1 in the 
Supplementary Appendix).
In the literature, we identified eight additional 
patients with both AA amyloidosis and hepato­
cellular adenomas. In at least six of these pa­
tients, amyloid­related symptoms also improved 
after surgical resection of the liver tumor (Table 
S4 in the Supplementary Appendix). We reviewed 
the liver histologic findings of two patients from 
the literature and identified features that were 
similar to those of our patient; inflammatory 
hepatocellular adenoma with SAA expression by 
the tumor and the adjacent parenchyma was in­
deed identified in both cases from the literature 
(Fig. S2 in the Supplementary Appendix).4,5 Bi­
refringent, SAA­positive amyloid deposits were 
also identified in the adenomas and adjacent liver 
tissue.
In conclusion, rare cases of inflammatory 
hepatocellular adenoma can induce massive SAA 
production by the tumor and nontumorous liver, 
leading to systemic AA amyloidosis. Molecular 
analyses identified a somatic rearrangement of the 
IL6 3′UTR leading to an autocrine interleukin­6 
secretion by the tumor. We speculate that this 
subset of AA amyloidosis may be treatable by 
surgical resection of the liver tumor.
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Sodium Thiosulfate and Cisplatin-Induced Hearing Loss
To the Editor: Brock and colleagues (June 21 
issue)1 report the results of International Liver 
Tumor Strategy Group (SIOPEL) 6, a randomized, 
controlled trial of sodium thiosulfate for protec­
tion from cisplatin­induced hearing loss. In addi­
tion to confirming the efficacy of sodium thio­
sulfate, as previously reported in the Children’s 
Oncology Group ACCL0431 trial,2 SIOPEL 6 pro­
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